Allergy Therapeutics (AGY)


Latest News

Allergy Therapeutics (AGY): Opening the door to registration

Hardman & Co Research Hardman & Co Research: Allergy Therapeutics (AGY): Opening the door to registration 21-May-2018 / 12:25 GMT/BST Hardman & Co Research: Opening the door to registration AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (SCI...

Allergy Therapeutics grass allergy product meets primary objectives

Allergy Therapeutics said Monday a study to explore the safety and response of its grass allergy product drug met its prim...

Positive top-line results from Grass Ph II study

RNS Number: 6504O Allergy Therapeutics PLC 21 May 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study - Primary endpoint met with highly statistically significant dose-response relationship established - - Optimal Phase III dose identi...

Publication of MCT Adjuvant Data

RNS Number: 8725N Allergy Therapeutics PLC 14 May 2018 Al l e r g y Th e r a p e u ti cs p l c (" A l l e r gy T he r a peu t i cs" or t he " Group " ) Allergy Therapeutics Publishes New Data Validating Mode of Action and Unique Adjuvant Properties of its Patented Adjuvant, Microcrystalline Tyrosine (MCT ), in The Journal of Immunology Novel Findings Further...

All News

30-12-16Grant of AwardsRNS
25-11-16Allergy Therapeutics resolutions passed at AGMStockMarketWire
24-11-16Result of AGMRNS
02-11-16Allergy Therapeutics granted EU patent StockMarketWire
02-11-16EU Patent Office grants patent for MCTRNS
27-10-16Issue of equity in respect of exercise of optionsRNS
24-10-16Annual Report and AccountsRNS
14-10-16Share of the week: Tipped to double againInteractive Investor
10-10-16New data from novel adjuvant systemRNS
03-10-16Issue of equity in respect of exercise of optionsRNS
29-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
29-09-16Director/PDMR ShareholdingRNS
28-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
28-09-16Director/PDMR ShareholdingRNS
26-09-16Allergy Therapeutics tipped to bounce backInteractive Investor
26-09-16Director Deals - Allergy Therapeutics PLC (AGY)StockMarketWire
26-09-16Director/PDMR ShareholdingRNS
26-09-16Hardman Research: Performance drives market shareRNS
26-09-16Allergy Therapeutics revenues up StockMarketWire
26-09-16Allergy Therapeutics revenues up StockMarketWire
26-09-16Allergy Therapeutics Preliminary ResultsRNS
21-09-16Broker Forecast - Numis issues a broker note on Allergy Therapeutics PLCStockMarketWire
21-09-16Allergy Therapeutics options exercised StockMarketWire
20-09-16Issue of equity in respect of exercise of optionsRNS
05-09-16Allergy Therapeutics schedules FY results StockMarketWire
05-09-16Notice of Preliminary ResultsRNS
31-08-16Allergy Therapeutics Plc to present at the Shares Investor Evening in London on 27th September 2016StockMarketWire
13-07-16Trading UpdateRNS
08-07-16Results of mite immunotherapy Acarovac PlusTRNS
27-06-16Findings from mEEC dose range finding study G204RNS
13-06-16Allergy Therapeutics' satellite symposium at EAACIStockMarketWire
13-06-16Allergy hosts Satellite Symposium at EAACIRNS
10-06-16Appointment of Finance DirectorRNS
18-05-16Why GlaxoSmithKline plc, Allergy Therapeutics plc and Consort Medical plc are a dying breedMotley Fool
09-05-16Allergy Therapeutics positive data from PQBirch204 studyStockMarketWire
09-05-16Positive Phase II DataRNS
21-04-16This list of shares keeps outperformingInteractive Investor
23-03-16Allergy Therapeutics options exercised StockMarketWire
23-03-16Issue of equity in respect of options exerciseRNS
17-03-16Allergy Therapeutics FD resigns StockMarketWire

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory